glp-1 study The trend: What the real-world data reveals GLP-1-based therapies for diabetes, obesity
Description
The active molecule (tirzepatide) is identical
After 30 days, the dose is to be increased to 7mg a day
Even if not every person with obesity should be on GLP-1 drugs, theres still a huge gap
Golden L
Clinical trials found substantial weight loss and improved cardiovascular outcomes associated with taking these medications
